Evidence-based urology: How does a randomized clinical trial achieve its designed goals?

Urology Journal

Volumn 8, Issue 2, 2011, Pages 88-96

  Bazargani, Homayoun Sadeghi ^a   Hajebrahimi, Sakineh ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Evidence based medicine; Randomized clinical trial; Urology

Indexed keywords

ARTICLE; DOUBLE BLIND PROCEDURE; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE BLIND PROCEDURE; STANDARD; UROLOGY;

DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SINGLE-BLIND METHOD; UROLOGY;

EID: 80052006103     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sajadi MM, Mansouri D, Sajadi MR. Ibn Sina and the clinical trial. Ann Intern Med. 2009;150:640-3.
2. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276:637-9.
3. Scales CD, Jr., Norris RD, Keitz SA, et al. A critical assessment of the quality of reporting of randomized, controlled trials in the urology literature. J Urol. 2007;177:1090-4; discussion 4-5.
4. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ. 2001;323:42-6.
5. Hanson BP. Designing, conducting and reporting clinical research. A step by step approach. Injury. 2006;37:583-94.
6. Domanski MJ, McKinlay S, Ovid Technologies I. Successful randomized trials: a handbook for the 21st century: Lippincott Williams & Wilkins; 2009. p.21-26.
7. Hrobjartsson A, Gotzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. J Clin Psychol. 2007;63:373-7.
8. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med. 2004;256:91-100.
9. Hrobjartsson A, Gotzsche PC. Placebo treatment versus no treatment. Cochrane Database Syst Rev. 2003CD003974.
10. Furukawa TA. Review: placebo is better than no treatment for subjective continuous outcomes and for treatment of pain. ACP J Club. 2002;136:20.
11. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344:1594-602.
12. Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol. 1997;50:1311-8.
13. Antal J. [Medical and ethical considerations of sham operation]. Magy Seb. 2007;60:233-8.
14. Clark PA. Sham surgery: to cut or not to cut--that is the ethical dilemma. Am J Bioeth. 2003;3:66-8.
15. Horng S, Miller FG. Ethical framework for the use of sham procedures in clinical trials. Crit Care Med. 2003;31:S126-30.
16. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med. 1999;341:992-6.
17. Miller FG. A response to commentators on "Sham surgery: an ethical analysis". Am J Bioeth. 2003;3:W36.
18. Miller FG. Sham surgery: an ethical analysis. Sci Eng Ethics. 2004;10:157-66.
19. Millar K. Clinical trial design: the neglected problem of asymmetrical transfer in cross-over trials. Psychol Med. 1983;13:867-73.
20. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference: Houghton, Mifflin and Company; 2002.p.253.
21. Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011;8:15-20.
22. Berger VW. Do not use blocked randomization. Headache. 2006;46:343; author reply -5.
23. Toorawa R, Adena M, Donovan M, Jones S, Conlon J. Use of simulation to compare the performance of minimization with stratified blocked randomization. Pharm Stat. 2009;8:264-78.
24. Xiao L, Lavori PW, Wilson SR, Ma J. Comparison of dynamic block randomization and minimization in randomized trials: a simulation study. Clin Trials. 2011;8:59-69.
25. Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. Stat Med. 2009;28:3329-46.
26. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359:696-700.
27. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004;25:143-56.
28. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002;136:254-9.
29. Nahler G, Mollet A. Dictionary of Pharmaceutical Medicine. 2 ed. New York: Springer; 2009.p.55.
30. Hajebrahimi S, Azaripour A, Sadeghi-Bazargani H. Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med. 2008;5:2880-5.
31. Weiss NS. Clinical epidemiology. In: Rothman KJ, Greenland S, Lash TL, eds. Modern epidemiology: Lippincott Williams & Wilkins; 2008:519-28.
32. Adalatkhah H, Sadeghi-Bazargani H, Pourfarzi F. Flutamide versus cyproterone acetate / ethinyl estradiol combination in moderate acne: a pilot clinical trial. Clinical, Cosmetic and Investigational Dermatology 2011(In press)